(MENAFN- Straits Research)
Hemostasis & Tissue Sealing Agents Market
The global hemostasis & tissue sealing agents market size was valued at USD 10 billion in 2025 and is projected to grow from USD 10.80 billion in 2026 to USD 19.96 billion by 2034, registering a CAGR of 7.98% during the forecast period from 2026 to 2034. North America dominated the hemostasis & tissue sealing agents market with a market share of 42.5% in 2025.
Hemostasis and tissue sealing agents are medical products used during surgical procedures to control bleeding and seal or close damaged tissues. They include hemostatic agents, tissue sealants, fibrin-based products, synthetic sealants, and other materials that promote clot formation or create a protective barrier over injured tissue. These products are widely used in general surgery, cardiovascular surgery, orthopedic procedures, and other surgical applications to reduce blood loss, support wound healing, and minimize complications.
Hemostasis & Tissue Sealing Agents Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 10 Billion
2026 Market Size: USD 10.80 Billion
2034 Projected Market Size: USD 19.96 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 7.98%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 42.5%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 9.65%
Segment Insights
By Product
Leading Segment: Topical Hemostat
Market Share in 2025: 58.7%
Download a Free Sample To learn more about this report,
Hemostasis & Tissue Sealing Agents Market Trends
Growing Adoption of Advanced Hemostatic Patches for Minimally Invasive Surgery
The hemostasis & tissue sealing agents market is increasingly shifting toward advanced hemostatic patches and sealants that can provide rapid bleeding control during complex and minimally invasive procedures. Manufacturers are focusing on products that are easier to apply, conform effectively to irregular tissue surfaces, and reduce dependence on conventional suturing or cauterization. This trend is supporting the hemostasis & tissue sealing agents market size as surgical volumes and demand for minimally invasive procedures continue to increase.
In June 2026, the U.S. FDA approved an expanded indication for Ethicon's ETHIZIA Hemostatic Patch, allowing its use in minimally invasive surgical procedures on the liver. The approval expands the clinical applications of the collagen-based hemostatic patch and demonstrates continued development of specialized bleeding-control products for minimally invasive surgery.
Increasing Development of Next-Generation Tissue Sealants and Multi-Functional Hemostatic Products
Another important trend is the development of next-generation products capable of combining hemostasis with tissue sealing and wound management. Manufacturers are focusing on biomaterials and formulations that provide rapid bleeding control while supporting tissue handling and reducing complications associated with conventional surgical techniques. This development is supporting hemostasis & tissue sealing agents market growth as hospitals increasingly seek efficient products that can address multiple surgical requirements.
In September 2025, the U.S. FDA approved an updated indication for Baxter's ARTISS fibrin sealant, expanding its use as an adjunct to hemostasis in adult and pediatric patients for adhering autologous skin grafts to surgically prepared burn wounds and tissue flaps during facial rhytidectomy. The approval highlights continued regulatory development of fibrin-based tissue-sealing products.
Hemostasis & Tissue Sealing Agents Market Dynamics
Market Drivers
Growing Need for Effective Bleeding Control During Surgery
The increasing number and complexity of surgical procedures is supporting the use of hemostatic agents and tissue sealants when conventional techniques such as sutures, ligatures, or cautery are insufficient or impractical. These products can help surgeons control bleeding, seal tissue surfaces, and support wound management across cardiovascular, hepatic, orthopedic, general, and other procedures. The need for rapid and reliable bleeding control is strengthening the hemostasis & tissue sealing agents market demand, particularly as minimally invasive and complex surgeries continue to require specialized products. The FDA recognizes multiple hemostatic and sealant technologies for use as adjuncts during surgical procedures.
In April 2026, the FDA approved an updated liquid formulation of Thrombin-JMI, supporting continued availability of topical thrombin as an aid to hemostasis during surgical procedures.
Market Restraints
Strict Regulatory Requirements and Product Safety Considerations
Hemostatic agents and tissue sealants are often used in critical surgical situations, requiring stringent regulatory oversight and careful evaluation of safety, effectiveness, manufacturing consistency, and clinical performance. Products can differ substantially in composition, mechanism, absorption characteristics, and appropriate surgical applications. These requirements influence the hemostasis & tissue sealing agents market analysis because manufacturers must maintain extensive quality systems and demonstrate that product changes do not compromise performance. Raw-material sourcing, sterilization, storage, and manufacturing controls can also add complexity and cost, particularly for biological or combination products.
In June 2026, the FDA approved a manufacturing-process supplement for Integra LifeSciences' absorbable collagen hemostatic agents involving changes to bacterial endotoxin testing methods, illustrating the ongoing quality-control requirements for these products.
Market Opportunities
Expansion of Advanced Hemostatic Patches and Minimally Invasive Applications
Innovation in absorbable patches, fibrin sealants, powders, matrices, and other delivery formats is creating opportunities to address bleeding across a wider range of procedures. Products designed for laparoscopic and minimally invasive surgery can provide surgeons with targeted bleeding control where conventional methods may be difficult to apply. These developments are shaping hemostasis & tissue sealing agents market trends toward easier delivery, faster application, improved tissue adherence, and broader surgical indications. Expansion into specialized procedures can also provide manufacturers with opportunities to develop products tailored to specific anatomical sites and bleeding conditions.
In June 2026, the FDA approved an expanded indication for ETHIZIA Hemostatic Patch to include minimally invasive surgical procedures on the liver, demonstrating continued development of advanced hemostatic products for less invasive procedures.
Market Challenges
Ensuring Reliable Hemostasis Across Diverse Surgical Conditions
Bleeding severity, tissue characteristics, anticoagulant use, surgical technique, and anatomical location can vary significantly between procedures, making consistent performance a major challenge. Hemostatic products must work effectively under different clinical conditions while minimizing complications and remaining easy for surgeons to apply. Manufacturers also need to balance rapid hemostasis with appropriate absorption, tissue compatibility, handling, and storage characteristics. These requirements remain important for the hemostasis & tissue sealing agents market report because surgeons need products that perform predictably when conventional bleeding-control techniques are insufficient.
In August 2026, FDA records showed multiple active product categories and approvals for absorbable hemostatic agents, including collagen-based products with thrombin and collagen products with polymeric additives, highlighting the continuing need to evaluate different mechanisms and formulations for reliable surgical bleeding control.
Hemostasis & Tissue Sealing Agents Market Segmentation Analysis
By Product
Topical Hemostat Segment Dominated the Market with 58.7% Share in 2025
The topical hemostat segment dominated the global hemostasis and tissue sealing agents market with a 58.7% market share in 2025, valued at USD 5.87 billion. Its leadership is supported by the widespread use of topical hemostatic products during surgical procedures to control bleeding at the site of injury. Their versatility across general surgery, cardiovascular procedures, orthopedic surgery, and other interventions continues to support demand.
Adhesives and tissue sealants continue to gain adoption where surgeons require effective tissue closure, sealing, or reinforcement. Their use can support minimally invasive procedures and help address specific surgical needs where conventional suturing or stapling may not provide the preferred approach.
Request Customization to receive a tailored report.
Speak to an Analyst to discuss market opportunities.
Hemostasis & Tissue Sealing Agents Market Regional Outlook
North America Hemostasis & Tissue Sealing Agents Market Analysis
North America's hemostasis & tissue sealing agents market accounted for 42.5% of the global market, reaching USD 4.25 billion in 2025, and is projected to grow at a CAGR of 7.85% during the forecast period. The region's leading position is supported by high surgical procedure volumes, advanced healthcare infrastructure, strong adoption of advanced hemostatic products, and increasing demand for effective bleeding-control solutions across surgical specialties.
United States Hemostasis & Tissue Sealing Agents Market Insights
The United States represents a major market in North America. High healthcare expenditure, a large volume of surgical procedures, advanced hospital infrastructure, and growing adoption of innovative hemostatic and tissue-sealing technologies continue to support regional market development.
Canada Hemostasis & Tissue Sealing Agents Market Insights
Canada's established healthcare infrastructure, increasing surgical activity, and growing adoption of advanced surgical products continue to support demand for hemostasis and tissue sealing agents.
Unlock Regional Insights to access country-level data, & regional trends.
Asia Pacific Hemostasis & Tissue Sealing Agents Market Analysis
The Asia Pacific hemostasis & tissue sealing agents market accounted for 21.4% of the global market, reaching USD 2.14 billion in 2025, and is projected to grow at a CAGR of 9.65% during the forecast period. The region records the fastest growth among the listed markets, driven by expanding healthcare infrastructure, rising surgical volumes, increasing healthcare expenditure, and growing adoption of advanced surgical and bleeding-control technologies.
China Hemostasis & Tissue Sealing Agents Market Insights
China represents a major market within the Asia Pacific. Expanding hospital infrastructure, increasing surgical procedures, and growing adoption of advanced medical technologies continue to drive demand for hemostasis and tissue sealing agents.
Japan Hemostasis & Tissue Sealing Agents Market Insights
Japan's advanced healthcare system, aging population, and high demand for sophisticated surgical technologies continue to support the adoption of hemostatic and tissue-sealing products.
India Hemostasis & Tissue Sealing Agents Market Insights
India's expanding healthcare infrastructure, increasing surgical volumes, and growing access to advanced medical technologies continue to create opportunities for hemostasis and tissue sealing agent manufacturers.
Europe Hemostasis & Tissue Sealing Agents Market Analysis
Europe's hemostasis & tissue sealing agents market accounted for 27.8% of the global market, reaching USD 2.78 billion in 2025, and is expected to register a CAGR of 7.35% during the forecast period. Increasing surgical procedures, improvements in healthcare infrastructure, and growing adoption of advanced bleeding-control technologies continue to support regional market growth.
Germany Hemostasis & Tissue Sealing Agents Market Insights
Germany represents a major European market. Its advanced healthcare infrastructure, high surgical capacity, and increasing use of innovative surgical technologies continue to support demand for hemostatic and tissue-sealing products.
United Kingdom Hemostasis & Tissue Sealing Agents Market Insights
The United Kingdom's established healthcare system, increasing surgical requirements, and growing adoption of advanced surgical technologies continue to create opportunities for market development.
Latin America Hemostasis & Tissue Sealing Agents Market Analysis
Latin America's hemostasis & tissue sealing agents market accounted for 5.1% of the global market, reaching USD 0.51 billion in 2025, and is expected to grow at a CAGR of 7.95% during the forecast period. Improvements in healthcare infrastructure, increasing surgical procedures, and growing availability of advanced medical products continue to support regional market development.
Brazil Hemostasis & Tissue Sealing Agents Market Insights
Brazil represents a major regional market. Its expanding healthcare sector, increasing surgical activity, and growing adoption of advanced surgical products continue to support market growth.
Middle East & Africa Hemostasis & Tissue Sealing Agents Market Analysis
The Middle East & Africa hemostasis & tissue sealing agents market accounted for 3.2% of the global market, reaching USD 0.32 billion in 2025, and is anticipated to grow at a CAGR of 7.25% during the forecast period. Healthcare infrastructure development, increasing surgical capacity, and growing adoption of advanced surgical technologies continue to support regional market expansion.
UAE Hemostasis & Tissue Sealing Agents Market Insights
The UAE's advanced healthcare infrastructure, growing medical tourism sector, and increasing adoption of sophisticated surgical technologies continue to support demand for hemostatic and tissue-sealing products.
Saudi Arabia Hemostasis & Tissue Sealing Agents Market Insights
Saudi Arabia's healthcare infrastructure expansion, increasing surgical capacity, and investments in advanced medical technologies continue to create opportunities for the hemostasis and tissue sealing agents market.
Hemostasis & Tissue Sealing Agents Market Competitive Landscape
The global hemostasis & tissue sealing agents market is highly competitive, with leading medical device, pharmaceutical, and biotechnology companies competing through topical hemostats, tissue sealants, fibrin sealants, synthetic sealants, thrombin-based products, collagen-based agents, and advanced surgical bleeding-control solutions. The major players in the market include B. Braun Medical, Inc.; Baxter; Advance Medical Solution (AMS) Group Plc; Integra Life Sciences Corporation; Johnson & Johnson; Cohera Medical, Inc.; Cohesion Technologies, Inc.; MIL Laboratories Pvt., Ltd.; Pfizer, Inc.; Covidien Plc.; Smith & Nephew; CryoLife, Inc.; HyperBranch Medical Technology; Biomet, Inc.; C.R. Bard, Inc.; and others.
Industry participants are focusing on developing fast-acting, biocompatible, easy-to-apply, and clinically effective hemostatic and tissue-sealing products that help control bleeding and support tissue repair during surgical procedures. Companies are investing in fibrin-based sealants, synthetic polymers, collagen-based hemostats, thrombin technologies, flowable hemostatic agents, and next-generation sealants designed for minimally invasive and complex surgical procedures. Growing surgical volumes, increasing adoption of minimally invasive procedures, demand for improved bleeding management, and the need to reduce surgical complications and procedure times are encouraging manufacturers to expand their hemostasis and tissue-sealing portfolios.
Johnson & Johnson: An Emerging Market Leader
Johnson & Johnson is a major participant in the global hemostasis and tissue sealing agents market through its Ethicon surgical business, which provides advanced solutions for bleeding control and tissue management. Its portfolio includes hemostatic agents and surgical technologies designed to support surgeons in managing bleeding during a wide range of procedures.
In 2026, Johnson & Johnson continued strengthening its surgical hemostasis and tissue-management portfolio, with an emphasis on advanced surgical technologies designed to improve bleeding control and procedural efficiency. The company's continued investment in innovative surgical solutions and its broad presence across hospitals and surgical specialties support growing demand for effective hemostatic and tissue-sealing technologies. These initiatives reinforce Johnson & Johnson's competitive position in the global hemostasis & tissue sealing agents market.
List of Key and Emerging Players in Hemostasis & Tissue Sealing Agents Market
B Braun Medical, Inc.
Baxter
Advance Medical Solution (AMS) Group Plc
Integra Life Sciences Corporation
Johnson & Johnson
Cohera Medical, Inc.
Cohesion Technologies, Inc.
MIL Laboratories Pvt., Ltd.
Pfizer, Inc.
Covidien Plc.
Smith & Nephew
CryoLife, Inc.
HyperBranch Medical Technology.
Biomet, Inc.
C R Bard, Inc.
Key Industry Developments
June 2026: Johnson & Johnson MedTech expanded its surgical solutions portfolio by advancing hemostatic agents and tissue management technologies. The company focused on improving surgical bleeding control, procedural efficiency, and patient outcomes across complex surgeries.
May 2026: Baxter expanded its surgical care portfolio by advancing hemostasis and tissue sealing solutions designed for operating room applications. The initiatives focused on improving bleeding management, surgical workflow efficiency, and patient recovery.
April 2026: Medtronic expanded its surgical technologies portfolio through advancements in hemostatic products and tissue sealing solutions. The company focused on developing innovative surgical tools to support effective bleeding control and minimally invasive procedures.
January 2026: BD (Becton, Dickinson and Company) expanded its surgical solutions capabilities through continued development of advanced surgical products, including technologies supporting wound management and procedural efficiency.
Report Scope
Comments
No comment